News

Gb Sciences is initiating a dose-ranging study of its investigational cannabinoid-based formulations in a rodent model of Parkinson’s disease next month as a step toward a first-in-human study. The study will determine the dose range of active ingredients to be used in human trials and potential side effects.

Treatment with GT-02287, an experimental oral therapy for Parkinson’s disease, corrected numerous damaging abnormalities associated with Parkinson’s in cell models, according to new data shared at a recent conference. “The data we presented at the Synuclein Meeting demonstrates further encouraging disease modifying potential for patients with Parkinson’s disease who currently…

Practicing tai chi for a year improved gait and balance in early-stage Parkinson’s disease patients, improving both inflammation and metabolism as well as brain function, according to a recent study. The study, “Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients,” was published…

Asceneuron’s experimental oral therapy ASN90 was found to significantly reduce the levels of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease — and improve motor function in a mouse model of the disease. The molecule — a suppressor of O–GlcNAcase (OGA), an enzyme involved…

During Parkinson’s Awareness Month, Aspen Neuroscience will launch a patient screening study to potentially advance ANPD001, its experimental, personalized neuron replacement therapy for Parkinson’s disease, into clinical trials. Considered to be the first of its kind, the Trial-Ready Cohort Study will involve several screening sites in the U.S.

Boston Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Vercise Neural Navigator with STIMVIEW XT, a visualization software that allows doctors to see in real-time the location of leads, or electrodes, within the brain of a Parkinson’s disease patient undergoing deep brain stimulation…

Nitrase Therapeutics has received a second grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the company’s research on nitrated alpha-synuclein, a new potential biomarker to help predict and diagnose Parkinson’s disease. “MJFF is the leading research accelerator for Parkinson’s disease treatments, and…

The Davis Phinney Foundation for Parkinson’s has brought the digital biomarker discovery platform nQ Medical aboard as a partner, with the goal of helping it get the patient insights needed to advance a technology aiming to improve life for those with Parkinson’s disease. Specifically, the foundation has convened a…

Treatment with liraglutide — approved to treat type 2 diabetes and obesity — improved non-motor function and the ability to perform daily life activities in people with Parkinson’s disease, according to initial top-line data from a Phase 2 trial. The therapy, sold by Novo Nordisk under the brand names…

A loss of social support due to the COVID-19 pandemic is tied to poorer mental health and more severe cognitive problems in people with Parkinson’s disease, a study based on a patient and caregiver survey reported. The study, “Impact of Isolation During the COVID-19 Pandemic on…